We are pleased to announce that a clinical trial, funded in part by the Neuroendocrine Tumor Research Foundation, has received the necessary regulatory approvals and is open to begin accruing patients. In particular, the clinical trial, Theranostics of Radiolabeled Somatostatin Antagonists 68Ga-DOTA-JR11 and 177Lu-DOTA-JR11 in Patients with Neuroendocrine Tumors from clinicaltrials.gov will enroll patients with carcinoid cancer for both treatment with the radionuclide, Lutetium-177 and imaging with the radionuclide Gallium-68. Wolfgang Weber, MD, PhD and Diane Reidy-Lagunes, MD, Memorial Sloan Kettering Cancer Center (MSKCC), are the lead researchers on this trial.
Specifically, this trial will assess the potential viability of 68 Ga-DOTA-JR11 and 177 Lu-DOTA-JR11 as a pair of diagnostic and therapeutic radiopeptides for neuroendocrine tumor patients. Gallium 68 is a radionuclide that can be used in diagnostic PET scans. Lutetium 177 is a radionuclide often used with somatostatin analogs to form therapeutic radiopeptides. This study will assess the sensitivity of gallium 68 and the safety of lutetium 177 when combined with the somatostatin antagonist, DOTA-JR11. The trial will employ a new approach to PRRT, the goal of which is to increase efficacy with fewer side effects than other PRRT trials of its kind. A total of 20 patients with progressive, metastatic and inoperable tumors will participate in the clinical trial. We expect the trial to accrue patients very rapidly from a list of those referred to MSKCC.